Wilmington Savings Fund Society FSB Has $272.98 Million Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Wilmington Savings Fund Society FSB boosted its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 15,322.2% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 555,661 shares of the medical equipment provider's stock after buying an additional 552,058 shares during the quarter. Intuitive Surgical makes up approximately 4.9% of Wilmington Savings Fund Society FSB's holdings, making the stock its 2nd largest holding. Wilmington Savings Fund Society FSB owned about 0.16% of Intuitive Surgical worth $272,980,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of ISRG. Massachusetts Financial Services Co. MA acquired a new stake in shares of Intuitive Surgical during the 3rd quarter worth approximately $558,807,000. International Assets Investment Management LLC grew its holdings in Intuitive Surgical by 49,383.6% during the 3rd quarter. International Assets Investment Management LLC now owns 1,090,619 shares of the medical equipment provider's stock worth $535,788,000 after acquiring an additional 1,088,415 shares during the period. FMR LLC raised its position in shares of Intuitive Surgical by 8.3% during the 3rd quarter. FMR LLC now owns 10,971,085 shares of the medical equipment provider's stock valued at $5,389,765,000 after acquiring an additional 838,793 shares during the last quarter. Strategic Financial Concepts LLC lifted its stake in shares of Intuitive Surgical by 40,221.4% in the 2nd quarter. Strategic Financial Concepts LLC now owns 266,121 shares of the medical equipment provider's stock valued at $1,184,000 after purchasing an additional 265,461 shares during the period. Finally, State Street Corp boosted its position in shares of Intuitive Surgical by 1.4% in the 3rd quarter. State Street Corp now owns 15,050,121 shares of the medical equipment provider's stock worth $7,393,673,000 after purchasing an additional 210,363 shares during the last quarter. 83.64% of the stock is currently owned by institutional investors.

Insider Transactions at Intuitive Surgical

In other news, CFO Jamie Samath sold 108 shares of the company's stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $542.06, for a total value of $58,542.48. Following the sale, the chief financial officer now directly owns 8,757 shares of the company's stock, valued at approximately $4,746,819.42. This represents a 1.22 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Robert Desantis sold 188 shares of Intuitive Surgical stock in a transaction dated Tuesday, October 29th. The stock was sold at an average price of $506.52, for a total value of $95,225.76. Following the transaction, the executive vice president now owns 5,506 shares of the company's stock, valued at $2,788,899.12. The trade was a 3.30 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 48,640 shares of company stock worth $25,233,553 in the last 90 days. Corporate insiders own 0.90% of the company's stock.

Intuitive Surgical Price Performance

ISRG stock traded up $1.12 during midday trading on Thursday, hitting $544.72. The company's stock had a trading volume of 1,211,159 shares, compared to its average volume of 1,441,064. The company's fifty day moving average price is $519.37 and its 200 day moving average price is $477.06. Intuitive Surgical, Inc. has a twelve month low of $320.22 and a twelve month high of $556.23. The stock has a market capitalization of $194.02 billion, a P/E ratio of 87.40, a PEG ratio of 5.41 and a beta of 1.38.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last released its earnings results on Thursday, October 17th. The medical equipment provider reported $1.56 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.24 by $0.32. Intuitive Surgical had a return on equity of 13.41% and a net margin of 28.51%. The business had revenue of $2.04 billion for the quarter, compared to the consensus estimate of $2.01 billion. Equities analysts expect that Intuitive Surgical, Inc. will post 5.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on ISRG shares. JPMorgan Chase & Co. upped their price objective on Intuitive Surgical from $495.00 to $575.00 and gave the company an "overweight" rating in a report on Friday, October 11th. Piper Sandler reiterated an "overweight" rating and issued a $538.00 price target (up from $495.00) on shares of Intuitive Surgical in a research report on Friday, October 18th. Truist Financial boosted their price objective on shares of Intuitive Surgical from $520.00 to $570.00 and gave the company a "buy" rating in a report on Monday, October 14th. Evercore ISI reiterated a "cautious" rating on shares of Intuitive Surgical in a report on Friday, October 18th. Finally, Stifel Nicolaus boosted their price target on shares of Intuitive Surgical from $525.00 to $610.00 and gave the company a "buy" rating in a report on Thursday, December 5th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $550.28.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.